Trial will test whether one trigger point is enough for chronic myofascial neck pain
Chronic myofascial neck pain often behaves like a moving target. More than one active trigger point can drive pain across the neck and cervicoscapular region, and day-to-day symptoms may reflect a small cluster of irritable muscle bands rather than a single dominant lesion. This randomized trial asks a practical question at the bedside: should clinicians inject only the trigger point that best reproduces the patient’s usual pain, or treat several active sites in the same session?
The study will compare two ultrasound-guided strategies in adults with chronic neck or cervicoscapular pain and active trigger points in at least two different muscles. One arm will receive a focused injection to the dominant active trigger point. The other will receive multi-target injections to the active trigger points identified within the protocol. Both groups will receive the same local anesthetic, the same technique, and only one treatment session. The design keeps the intervention narrow enough to isolate the question that matters clinically: whether more injections buy meaningful extra relief or simply add burden.
Ultrasound guidance keeps the comparison centered on injection extent
Investigators will treat the upper trapezius, levator scapulae, and infraspinatus muscles bilaterally before randomization. Active trigger points and the dominant active trigger point will be identified first, then group assignment will be revealed. In the focused arm, only the trigger point most closely linked to the participant’s usual pain will be injected. In the multi-target arm, all active trigger points named in the study protocol will be treated, while latent trigger points will be left alone.
Each treated site will receive 1 mL of 1% lidocaine. The protocol avoids extra needle redirection and does not pursue a local twitch response, which helps keep the mechanics of the procedure consistent across groups. Ultrasound guidance is important here because it reduces uncertainty about where the needle is going and keeps the comparison focused on treatment breadth rather than technical variability. When a trial is trying to answer a small procedural question, technical noise can obscure the answer quickly.
Pain relief at 4 weeks will be the central readout
The primary endpoint is average neck and cervicoscapular pain intensity over the previous 7 days at 4 weeks, measured on a 0 to 10 Numeric Rating Scale. That choice fits the biology of trigger point pain, which can fluctuate after needling, local anesthetic exposure, and short-term post-procedure soreness. A 4-week endpoint should capture whether relief lasts beyond the immediate anesthetic window and whether the added injections in the multi-target arm translate into a more durable clinical effect.
Secondary outcomes extend the picture beyond pain intensity. The study will measure pain at 1 week, Neck Disability Index score at 4 weeks, global improvement, procedure duration, pain 24 hours after the procedure, and adverse events. Those measures matter because myofascial pain is not just a sensory complaint; it restricts head turning, limits work and sleep, and makes everyday neck loading more difficult. A strategy that lowers pain but increases post-procedure discomfort, time, or adverse effects may not be worth the extra procedural effort.
One extra needle pass can change the entire patient experience.
Why the question matters in myofascial pain practice
The clinical appeal of multi-target injection is obvious. If several active trigger points contribute to referred pain and muscle guarding, treating only the dominant site may leave part of the pain generator untouched. In that setting, a broader injection strategy could plausibly reduce nociceptive input from multiple muscles, improve local perfusion, and interrupt the taut-band physiology that sustains myofascial pain. Better deactivation of peripheral pain sources could also lower central sensitization over time, which is one reason more extensive treatment sounds attractive on paper.
The counterargument is equally strong. More trigger points mean more needle insertions, a larger total volume of local anesthetic, a longer procedure, and potentially more immediate soreness. In a condition that already limits neck movement and often heightens sensitivity to touch, additional procedural burden could outweigh marginal gains. If focused injection works nearly as well as multi-target treatment, clinicians could avoid unnecessary injections while still addressing the main pain generator. That would simplify care without sacrificing the physiologic logic of trigger point therapy.
The trial’s structure reflects that tension. It is built to determine not only whether multi-target treatment improves pain, but whether any added benefit is large enough to justify the extra procedural cost in the room.
Blinding, eligibility, and the population under study
The trial will enroll adults 18 to 65 years old with chronic pain for at least 3 months, an average pain score of at least 4 out of 10 over the previous week, and active trigger points in at least two muscles among the upper trapezius, levator scapulae, and infraspinatus. Patients with cervical radiculopathy, myelopathy, fibromyalgia, major structural explanations for pain, recent trigger point procedures, infection at the injection site, bleeding risk, pregnancy, or major communication impairment are excluded. Those criteria narrow the cohort to a fairly specific myofascial phenotype and reduce the chance that another disorder is driving the pain signal.
Masking is double for participants and outcomes assessment. Participants will not know which strategy they received, and follow-up assessments at 1 and 4 weeks will be performed by a blinded assessor. The clinician performing the injections cannot be masked because the number of treated trigger points differs between groups. Even so, the blinded outcome evaluation should help preserve the integrity of the pain and disability measurements, which are vulnerable to expectation effects in procedural studies.
A focused answer for a common procedural dilemma
This study is modest in size, with an estimated enrollment of 100 participants, and it is not yet recruiting. Its value lies less in scale than in precision. Chronic myofascial neck pain is common, persistent, and often treated with a blend of empiricism and experience. This trial will ask whether a more extensive injection pattern genuinely improves patient-centered outcomes or whether the dominant trigger point carries most of the therapeutic weight.
If the focused strategy performs nearly as well as the multi-target approach, the results would support a smaller, less burdensome procedure. If the broader strategy wins clearly on pain, disability, or global improvement, clinicians will have a stronger basis for treating more than one trigger point in the same session. The key uncertainty is procedural value: how much extra relief is enough to justify more injections, more time, and more immediate discomfort for patients already living with chronic neck pain.